致心律失常性心肌病中免疫反应的治疗性调节
本研究在体外ACM模型、Dsg2mut/mut小鼠模型及患者诱导多能干细胞来源心肌细胞中,发现核因子-κB信号激活是ACM的突出特征,小分子抑制剂Bay 11-7082可预防ACM疾病特征,提示靶向炎症通路可能成为ACM的新治疗策略。
要点
- 核因子-κB信号在ACM体外、小鼠及患者心肌细胞中均激活。
- Bay 11-7082可预防ACM模型中的结构、功能及电学异常。
- 靶向炎症通路可能成为ACM的机制性治疗新策略。
核心结论
- 炎症信号在ACM中激活并驱动疾病关键特征,靶向炎症通路可能是有效的新机制治疗。
研究设计与样本
- 研究在体外ACM模型(新生大鼠心室肌细胞表达JUP2157del2)、Dsg2mut/mut小鼠模型及患者诱导多能干细胞来源心肌细胞中开展。
主要发现
- 核因子-κB信号激活表现为phospho-RelA/p65表达增加和核内积聚,在体外ACM模型和Dsg2mut/mut小鼠中均出现。
- Bay 11-7082在体外预防闰盘蛋白异常再分布、心肌细胞凋亡和炎性细胞因子释放,在体内预防心肌坏死和纤维化、左心室收缩功能障碍及心电图异常。
- Dsg2mut/mut小鼠心脏炎性细胞因子和趋化分子水平显著升高,Bay 11-7082可减弱这些升高,其有益效应与选定细胞因子产生被阻断的程度相关。
- 患者ACM来源心肌细胞中核因子-κB信号也激活,基础条件下产生和分泌大量炎性细胞因子,Bay 11-7082可大幅减少。
临床怎么用
- 靶向炎症通路可能作为ACM的机制性治疗方向,但需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammation is a prominent feature of arrhythmogenic cardiomyopathy (ACM), but whether it contributes to the disease phenotype is not known. METHODS: To define the role of inflammation in the pathogenesis of ACM, we characterized nuclear factor-κB signaling in ACM models in vitro and in vivo and in cardiac myocytes from patient induced pluripotent stem cells. RESULTS: Activation of nuclear factor-κB signaling, indicated by increased expression and nuclear accumulation of phospho-RelA/p65, occurred in both an in vitro model of ACM (expression of JUP2157del2 in neonatal rat ventricular myocytes) and a robust murine model of ACM (homozygous knock-in of mutant desmoglein-2 [Dsg2mut/mut]) that recapitulates the cardiac manifestations seen in patients with ACM. Bay 11-7082, a small-molecule inhibitor of nuclear factor-κB signaling, prevented the development of ACM disease features in vitro (abnormal redistribution of intercalated disk proteins, myocyte apoptosis, release of inflammatory cytokines) and in vivo (myocardial necrosis and fibrosis, left ventricular contractile dysfunction, electrocardiographic abnormalities). Hearts of Dsg2mut/mut mice expressed markedly increased levels of inflammatory cytokines and chemotactic molecules that were attenuated by Bay 11-7082. Salutary effects of Bay 11-7082 correlated with the extent to which production of selected cytokines had been blocked. Nuclear factor-κB signaling was also activated in cardiac myocytes derived from a patient with ACM. These cells produced and secreted abundant inflammatory cytokines under basal conditions, and this was also greatly reduced by Bay 11-7082. CONCLUSIONS: Inflammatory signaling is activated in ACM and drives key features of the disease. Targeting inflammatory pathways may be an effective new mechanism-based therapy for ACM.
引用
- Chelko SP, Asimaki A, Lowenthal J, et al. Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy. Circulation. 2019. PMID: 31533459. doi:10.1161/CIRCULATIONAHA.119.040676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。